Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 79

1.

Potential mechanisms of calcium dependent regulation of the mammalian cell cycle revealed by comprehensive unbiased label-free nLC-MS/MS quantitative proteomics.

Kwasnik A, von Kriegsheim A, Irving A, Pennington SR.

J Proteomics. 2017 Aug 18. pii: S1874-3919(17)30269-5. doi: 10.1016/j.jprot.2017.08.006. [Epub ahead of print]

PMID:
28823580
2.

Absolute Quantification of Toxicological Biomarkers via Mass Spectrometry.

Lau TYK, Collins BC, Stone P, Tang N, Gallagher WM, Pennington SR.

Methods Mol Biol. 2017;1641:337-348. doi: 10.1007/978-1-4939-7172-5_19.

PMID:
28748474
3.

Probing the prostate tumour microenvironment I: impact of glucose deprivation on a cell model of prostate cancer progression.

Tonry C, Armstrong J, Pennington SR.

Oncotarget. 2017 Feb 28;8(9):14374-14394. doi: 10.18632/oncotarget.14605.

4.

Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment.

Staunton L, Tonry C, Lis R, Espina V, Liotta L, Inzitari R, Bowden M, Fabre A, O'Leary J, Finn SP, Loda M, Pennington SR.

Mol Cancer Res. 2017 Mar;15(3):281-293. doi: 10.1158/1541-7786.MCR-16-0358. Epub 2017 Jan 5.

PMID:
28057717
5.

Protein-Protein Interaction Detection Via Mass Spectrometry-Based Proteomics.

Turriziani B, von Kriegsheim A, Pennington SR.

Adv Exp Med Biol. 2016;919:383-396. Review.

PMID:
27975227
6.

Proteomes, Their Compositions and Their Sources.

Kwasnik A, Tonry C, Ardle AM, Butt AQ, Inzitari R, Pennington SR.

Adv Exp Med Biol. 2016;919:3-21. Review.

PMID:
27975210
7.

The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer.

Tonry CL, Leacy E, Raso C, Finn SP, Armstrong J, Pennington SR.

Diagnostics (Basel). 2016 Jul 18;6(3). pii: E27. doi: 10.3390/diagnostics6030027. Review.

8.

Clinical translation of MS-based, quantitative plasma proteomics: status, challenges, requirements, and potential.

Percy AJ, Byrns S, Pennington SR, Holmes DT, Anderson NL, Agreste TM, Duffy MA.

Expert Rev Proteomics. 2016 Jul;13(7):673-84. doi: 10.1080/14789450.2016.1205950. Epub 2016 Jul 8.

PMID:
27341553
9.

Oral squamous cell carcinoma: Key clinical questions, biomarker discovery, and the role of proteomics.

Malik UU, Zarina S, Pennington SR.

Arch Oral Biol. 2016 Mar;63:53-65. doi: 10.1016/j.archoralbio.2015.11.017. Epub 2015 Nov 25. Review.

PMID:
26691574
10.

Developing clinically relevant biomarkers in inflammatory arthritis: A multiplatform approach for serum candidate protein discovery.

McArdle A, Qasim Butt A, Szentpetery A, de Jager W, de Roock S, FitzGerald O, Pennington SR.

Proteomics Clin Appl. 2016 Jun;10(6):691-8. doi: 10.1002/prca.201500046. Epub 2015 Nov 9.

PMID:
26332844
11.

A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-╬▒ treatment of psoriatic arthritis.

Collins ES, Butt AQ, Gibson DS, Dunn MJ, Fearon U, van Kuijk AW, Gerlag DM, Pontifex E, Veale DJ, Tak PP, FitzGerald O, Pennington SR.

Proteomics Clin Appl. 2016 Jun;10(6):645-62. doi: 10.1002/prca.201500051. Epub 2015 Sep 28.

PMID:
26108918
12.

Early biomarkers of joint damage in rheumatoid and psoriatic arthritis.

Mc Ardle A, Flatley B, Pennington SR, FitzGerald O.

Arthritis Res Ther. 2015 Jun 1;17:141. doi: 10.1186/s13075-015-0652-z. Review.

13.

Discovery and Longitudinal Evaluation of Candidate Protein Biomarkers for Disease Recurrence in Prostate Cancer.

Tonry CL, Doherty D, O'Shea C, Morrissey B, Staunton L, Flatley B, Shannon A, Armstrong J, Pennington SR.

J Proteome Res. 2015 Jul 2;14(7):2769-83. doi: 10.1021/acs.jproteome.5b00041. Epub 2015 Jun 5.

PMID:
26011319
14.

Psoriatic arthritis under a proteomic spotlight: application of novel technologies to advance diagnosis and management.

Butt AQ, McArdle A, Gibson DS, FitzGerald O, Pennington SR.

Curr Rheumatol Rep. 2015 May;17(5):35. doi: 10.1007/s11926-015-0509-0. Review.

PMID:
25895652
15.

Application of a discovery to targeted LC-MS proteomics approach to identify deregulated proteins associated with idiosyncratic liver toxicity in a rat model of LPS/diclofenac co-administration.

Ramm S, Morissey B, Hernandez B, Rooney C, Pennington SR, Mally A.

Toxicology. 2015 May 4;331:100-11. doi: 10.1016/j.tox.2015.03.004. Epub 2015 Mar 13.

PMID:
25772430
16.

Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis.

Ademowo OS, Hernandez B, Collins E, Rooney C, Fearon U, van Kuijk AW, Tak PP, Gerlag DM, FitzGerald O, Pennington SR.

Ann Rheum Dis. 2016 Jan;75(1):234-41. doi: 10.1136/annrheumdis-2014-205417. Epub 2014 Sep 3.

PMID:
25187158
17.

Why have so few proteomic biomarkers "survived" validation? (Sample size and independent validation considerations).

Hernández B, Parnell A, Pennington SR.

Proteomics. 2014 Jul;14(13-14):1587-92. doi: 10.1002/pmic.201300377. Epub 2014 May 16.

PMID:
24737731
18.

Synovial membrane protein expression differs between juvenile idiopathic arthritis subtypes in early disease.

Finnegan S, Robson J, Scaife C, McAllister C, Pennington SR, Gibson DS, Rooney ME.

Arthritis Res Ther. 2014 Jan 13;16(1):R8. doi: 10.1186/ar4434.

19.

Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy.

Morrissey B, O'Shea C, Armstrong J, Rooney C, Staunton L, Sheehan M, Shannon AM, Pennington SR.

Proteomics Clin Appl. 2013 Jun;7(5-6):316-26. doi: 10.1002/prca.201300004.

PMID:
23670859
20.

New insight into the functions of the interleukin-17 receptor adaptor protein Act1 in psoriatic arthritis.

Doyle MS, Collins ES, FitzGerald OM, Pennington SR.

Arthritis Res Ther. 2012 Oct 31;14(5):226. doi: 10.1186/ar4071. Review.

Supplemental Content

Loading ...
Support Center